Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Inventory (2020 - 2025)

Xeris Biopharma Holdings' Change in Inventory history spans 6 years, with the latest figure at $4.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 27.86% year-over-year to $4.0 million, compared with a TTM value of $19.3 million through Dec 2025, up 119.61%, and an annual FY2025 reading of $19.3 million, up 119.61% over the prior year.
  • Change in Inventory for Q4 2025 was $4.0 million at Xeris Biopharma Holdings, down from $4.1 million in the prior quarter.
  • The five-year high for Change in Inventory was $7.6 million in Q2 2025, with the low at $148000.0 in Q2 2022.
  • Average Change in Inventory over 5 years is $2.9 million, with a median of $2.3 million recorded in 2021.
  • Year-over-year, Change in Inventory tumbled 95.49% in 2022 and then soared 4922.3% in 2023.
  • Tracing XERS's Change in Inventory over 5 years: stood at $2.3 million in 2021, then skyrocketed by 142.08% to $5.5 million in 2022, then plummeted by 74.55% to $1.4 million in 2023, then skyrocketed by 123.91% to $3.1 million in 2024, then rose by 27.86% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Change in Inventory are $4.0 million (Q4 2025), $4.1 million (Q3 2025), and $7.6 million (Q2 2025).